Key Highlights

  • SenesTech posted record quarterly Revenue of $770,000 and its highest-ever gross Margin of 73.6%, with E-commerce sales exceeding direct B2B revenue for the first time after the company brought Amazon channel management in-house.
  • Online revenue more than tripled sequentially, with Amazon sales rising roughly fivefold in the first full quarter under direct company management, while active subscriber counts more than doubled quarter over quarter.
  • Despite the operational improvement, cash used in operations rose to $3.638 million for the half from $2.707 million a year earlier, with management stating existing cash funds operations only through the end of the first quarter of fiscal 2027.

SenesTech, Inc. (NASDAQ:SNES) sells something the pest-control industry has never had much of: rodent birth control. Rather than poisoning rats and mice, its ContraPest liquid bait and newer Evolve soft-bait pellets suppress fertility so populations shrink over time. The idea has always been commercially interesting. Turning it into a repeatable revenue stream has been the hard part.

That is why the quarter reported on 5 August 2026 has drawn attention. SenesTech posted record quarterly revenue and its highest-ever gross margin, and for the first time its online channel out-sold its direct business-to-business salesforce, following a decision to pull e-commerce management in-house.

Investors are weighing that against an unforgiving balance sheet. The Phoenix, Arizona company carries a $146.4 million accumulated deficit, held about $5.1 million of cash at 30 June 2026, and has flagged substantial doubt about its ability to continue as a going concern. The stock closed at $1.25 on 13 August 2026, a Market Capitalisation near $6.8 million.

What Happened

SenesTech reported second-quarter 2026 revenue of $770,000, up 56% sequentially and 23% from the $625,000 recorded a year earlier. Gross margin reached a company record 73.6%, up from 68.5% in the first quarter, and Gross Profit rose 68% sequentially to $567,000.

The driver was e-commerce. Online revenue more than tripled sequentially to a record $511,000, exceeding direct B2B revenue of $259,000. Amazon sales rose roughly fivefold to $349,000 in the first full quarter the company managed that channel itself, setting records for order and subscriber counts. Its own website contributed $155,000.

Two days earlier the company said its active online subscriber base had more than doubled quarter-on-quarter, with overall e-commerce up 186%. Direct-to-consumer subscription revenue hit a record $104,000, up 89%, and combined subscribers rose 117%. Michael Edell, who became President and Chief Executive Officer in May 2026 after serving as interim Chief Operating Officer, said subscriber growth was among the clearest signals the strategy is working.

Why It Matters

For a company this small, the composition of revenue matters as much as the size of it. Subscription orders repeat without a new sales cycle, and rodent fertility control is inherently a long-running programme rather than a one-off purchase, which makes Recurring Billing a natural fit.

Taking over Amazon management directly also explains the margin jump, stripping out an intermediary layer and handing SenesTech control of pricing, listings and subscription mechanics. In the first quarter of 2026, third-party managed revenue had collapsed to $17,000 from $157,000 a year earlier as that transition completed.

The Numbers

Net loss narrowed to $1.8 million from $2.1 million in the first quarter, with an adjusted EBITDA loss of $1.37 million and operating expenses of $2.43 million. First-half revenue was $1.26 million, up 14%. The first quarter had carried $443,000 of severance and one-off legal costs.

Evolve, the pelletised product aimed at field and agricultural use, generated $662,000, or 86% of product revenue, confirming it has displaced the original ContraPest liquid formulation as the commercial engine.

The Balance Sheet is the constraint. Cash stood at $5.08 million at 30 June 2026, down from $7.6 million at the end of 2025, against stockholders' Equity of $6.05 million. Cash used in operations over the first half was $3.638 million against $2.707 million a year earlier, so burn is rising even as revenue improves.

There were 5,423,542 shares outstanding as of 4 August 2026, reflecting the 1-for-10 reverse split completed in July 2024. The filing states existing cash is expected to fund operations only through the end of the first quarter of fiscal 2027, with revenue growth, expense control and its at-the-market Facility cited as the remedies.

What It Means for the Company

SenesTech is running a channel experiment in public, and this is the first quarter where the results are legible. A 73.6% gross margin on a product sold by subscription is an attractive unit economic profile; the question is whether Volume can scale fast enough to cover a roughly $2.4 million quarterly cost base.

The company is building out the B2B side rather than abandoning it. Jack Karabees, appointed Executive Vice President of Sales on 29 June 2026, brings more than 30 years of B2B sales leadership, including senior roles at Intercept Telehealth and at Consult A Doctor, acquired by Teladoc Health.

In July it began deploying paid rodent assessment services, using an internally built artificial-intelligence tool that reads tracking-product data to size an infestation before recommending treatment. It is a land-and-expand motion: sell the diagnostic, then sell the product.

Risks Investors Should Watch

Funding is the dominant risk. With a runway stated only into early fiscal 2027 and an explicit going-concern warning, further equity issuance looks likely, and at a market capitalisation under $10 million any raise would be meaningfully dilutive to a 5.4 million share base.

Concentration is next. The filing flags Amazon at roughly 32% to 45% of sales, so a listing suspension or fee increase would hit revenue directly. The company also states plainly that market acceptance of fertility-based pest control remains unproven, an honest description of a category sold against cheap, familiar rodenticides.

Listing status is worth monitoring. Shares traded at $1.25 against a 52-week range of $1.15 to $5.35, limited headroom above Nasdaq's $1.00 minimum bid requirement, though stockholders' equity sits well above the Nasdaq Capital Market threshold. No deficiency notice appears in the 2026 releases and filings reviewed here.

What Comes Next

The next scheduled milestone is third-quarter results, likely in early November. The figures to watch are whether e-commerce holds above direct B2B revenue, whether the 73.6% gross margin proves durable, and whether subscriber additions continue near the second quarter's pace.

Investors will also look for evidence that assessment services convert into orders, for contribution from newer distribution such as the June 2026 Bermuda agreement with Animal and Garden House, and for any financing announcement. In July, an Evolve programme at a 400-acre farm in Dalhart, Texas was reported to have cut rodent activity by roughly 80%.

Conclusion

SenesTech's channel shift is producing genuinely measurable results: taking Amazon management in-house both tripled online revenue and drove the company's best-ever gross margin, and subscription-based sales fit naturally with a product designed for ongoing use rather than one-time purchase. The unit Economics on a 73.6% margin subscription Business are attractive if volume can scale. But burn is rising even as revenue improves, cash used in operations grew year over year despite the better top line, and the company's own filing caps its runway at the end of the first fiscal quarter of 2027. With roughly a third to nearly half of sales concentrated in a single Amazon channel, the third-quarter question isn't just whether e-commerce keeps outpacing B2B, it's whether that growth can outrun the cash burn before the stated runway expires.